TAS1R1, TAS1R3, TLR2, TLR4, CA6 Gene Polymorphism on Dental Caries

April 12, 2021 updated by: Gul Yildiz Telatar, Recep Tayyip Erdogan University Training and Research Hospital

Variants in Taste Genes on Caries Risk and Caries Activity Status

The aim of this study is to examine the effects of TAS1R1, TAS1R3, TLR2, TLR4, CA6, gene polymorphism on caries risk in adults.

Study Overview

Detailed Description

To date, genes can be grouped into categories based on the factor influencing dental caries. The major candidate gene categories to date include enamel formation genes, immune response genes, genes related to saliva, and genes related to taste and dietary habits.

CA6 exists in the human saliva and has a critical role of buffering, immune response and taste.Toll-like receptors are expressed in the tongue gustatory papillae where they may initiate immune responses to pathogens.Genetic variations in the TAS1R1 and TAS1R3 for umami cause perception of these tastes differently.

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rize, Turkey, 53000
        • Recep Tayyip Erdoğan University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 44 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Power analysis was performed with the G-Power software package. It was determined that a total of 200 patients will be needed: 100 (DMFT ≤ 5) for the low caries risk group and 100 (DMFT ≥ 14) for the high caries risk group

Description

Inclusion Criteria:

  • adult be between 25 and 44 years old
  • subject has DMFT (Decayed, Missing, Filled, Permanent Tooth) ≥ 5, or, DMFT ≥14
  • same oral health, diet and socioeconomic status

Exclusion Criteria:

  • systemic or genetic disorders
  • orthodontic appliances
  • pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
high caries risk
100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)
DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
Other Names:
  • DNA isolation, genotyping

Dental caries lesions of all patient scored as initial, moderate or advanced caries

Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed

low caries risk
100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)
DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
Other Names:
  • DNA isolation, genotyping

Dental caries lesions of all patient scored as initial, moderate or advanced caries

Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Past caries experience
Time Frame: 4 months
Each tooth will be examined and recorded as decayed, missing, or filled (DMFT). Caries will be defined in accordance with the World Health Organization (WHO 1997) criteria.
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gül Yıldız Telatar, Dr., Recep Tayyip Erdogan University Dentistry Faculty

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2018

Primary Completion (Actual)

October 15, 2019

Study Completion (Actual)

November 20, 2019

Study Registration Dates

First Submitted

August 21, 2019

First Submitted That Met QC Criteria

August 21, 2019

First Posted (Actual)

August 26, 2019

Study Record Updates

Last Update Posted (Actual)

April 15, 2021

Last Update Submitted That Met QC Criteria

April 12, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2016/30

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data will be available within 6 months of study completion

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on High Caries Risk

Clinical Trials on high caries risk

Subscribe